Literature DB >> 28144982

A systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis frequency.

Ronald J Gurrera1.   

Abstract

OBJECTIVE: To examine sex and age distributions in neuroleptic malignant syndrome (NMS) patients based on a systematic literature review.
METHOD: EMBASE and PubMed databases were searched to identify any observation of NMS published from January 1, 1998 through November 1, 2014 that was accessible and interpretable (using language translation software). Redundant and equivocal reports were excluded. Sex ratio and age distributions were examined using standard graphical techniques and measures of association.
RESULTS: Twenty-eight independent sex ratio estimates were included. Males predominated in most (75%) estimates with an overall median sex ratio of 1.47 (95% CI, 1.20-1.80). NMS incidence peaked at age 20-25 years and declined steadily thereafter, with males consistently outnumbering females at all but the oldest age intervals.
CONCLUSION: NMS patients are 50% more likely to be males, and NMS is most likely to occur in young adulthood. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  age factors; neuroleptic malignant syndrome; risk factors; sex

Mesh:

Year:  2017        PMID: 28144982     DOI: 10.1111/acps.12694

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  3 in total

1.  Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993-2015.

Authors:  Michael Schneider; Johannes Regente; Timo Greiner; Stephanie Lensky; Stefan Bleich; Sermin Toto; Renate Grohmann; Susanne Stübner; Martin Heinze
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-11-30       Impact factor: 5.270

Review 2.  [Neuroleptic malignant syndrome].

Authors:  R Knorr; J Schöllkopf; E Haen
Journal:  Nervenarzt       Date:  2018-03       Impact factor: 1.214

3.  A retrospective analysis of cases with neuroleptic malignant syndrome and an evaluation of risk factors for mortality.

Authors:  Aynur Sahin; Mustafa Cicek; Ozgen Gonenc Cekic; Mucahit Gunaydin; Demet Saglam Aykut; Ozgur Tatli; Yunus Karaca; Mualla Aylin Arici
Journal:  Turk J Emerg Med       Date:  2017-11-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.